You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
Medical Sciences Forum
Submit to MSF
Submit a Proposal
  • 34 daysTime to First Decision

Medical Sciences Forum, Volume 3, Issue 1

IECC 2021 2021 - 17 articles

The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response

Online | 1–14 February 2021

Volume Editors:
Nicola Curtin, Newcastle University, UK
Helen E. Bryant, University of Sheffield, UK

Cover Story: The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response (IECC2021) brought together researchers in basic, translational, and clinical research to discuss the current research and the opportunities and obstacles that lie ahead of the field as we seek to translate the concepts of synthetic lethality, gene addiction and checkpoint inhibition into cancer therapies together. We hope that you enjoy reading the publications that resulted from this conference addressing a variety of research topics that cover the following areas: DNA function and its dysregulation in cancer, role of the DDR in immune signaling, targeted therapies exploiting DDR dysregulation and translation of determinants of sensitivity to predictive biomarkers, and clinical studies with DDR-targeted therapies.
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (17)

  • Proceeding Paper
  • Open Access
2 Citations
1,412 Views
7 Pages
Download PDF

Space and Time in the Universe of the Cell Nucleus after Ionizing Radiation Attacks: A Comparison of Cancer and Non-Cancer Cell Response

  • Michael Hausmann,
  • Charlotte Neitzel,
  • Hannes Hahn,
  • Ruth Winter,
  • Iva Falkova,
  • Dieter W. Heermann,
  • Götz Pilarczyk,
  • Georg Hildenbrand,
  • Harry Scherthan and
  • Martin Falk
Med. Sci. Forum2021, 3(1), 15;https://doi.org/10.3390/IECC2021-09219

31 January 2021

DNA double-strand breaks (DSBs) are known to be the most serious lesions in irradiated cells. Several protein pathways exist for repair. The mechanisms by which cells determine a specific pathway for repair remain poorly understood. DSB induction and...

Full Article
  • Abstract
  • Open Access
1,140 Views
1 Page
Download PDF

Changes in Gene Expression of Metalloproteinases-2 and -9 and Their Inhibitors TIMP2 and TIMP3 in Human Glioma Cells Exposed to Low Levels of Fluoride

  • Magdalena Nowak,
  • Marta Skórka-Majewicz and
  • Wojciech Żwierełło
Med. Sci. Forum2021, 3(1), 14;https://doi.org/10.3390/IECC2021-09229

31 January 2021

Introduction: Fluorine compounds are common environmental pollutants and may excessively penetrate the human body, especially the brain (fluoride penetrates the blood–brain barrier). Some of the latest studies have shown that fluoride may inter...

Full Article
  • Abstract
  • Open Access
1,183 Views
1 Page
Download PDF

Exploring Sensitivity to Replicative Stress in BRCA-Deficient Triple Negative Breast Cancer

  • Imene Tabet,
  • Carolina Velázquez,
  • Esin Orhan,
  • Lise Fenou,
  • Laura Boudarel,
  • William Jacot,
  • Claude Sardet and
  • Charles Theillet
Med. Sci. Forum2021, 3(1), 12;https://doi.org/10.3390/IECC2021-09226

31 January 2021

In triple negative breast cancer (TNBC), chemotherapy is the only systemic treatment and sustained remissions are rare. We propose to widen therapeutic options. About 30% of TNBC tumors are BRCA1-deficient, presenting defective DNA repair and increas...

Full Article
  • Abstract
  • Open Access
1,020 Views
1 Page
Download PDF

The Cytotoxic Effect of 64Cu/NOTA-Terpyridine Platinum Conjugate, as a Novel Chemoradiotherapy Agent

  • Meysam Khosravifarsani,
  • Samia Ait-Mohand,
  • Benoit Paquette,
  • Léon Sanche and
  • Brigitte Guérin
Med. Sci. Forum2021, 3(1), 7;https://doi.org/10.3390/IECC2021-09220

31 January 2021

Colorectal cancer is one of the most prevalent cancers worldwide that displays both intrinsic and acquired resistance to platinum-based chemotherapeutic agents (Pt-CAs). To overcome such resistance, new classes of Pt-CAs have been proposed, including...

Full Article
  • Abstract
  • Open Access
1,299 Views
2 Pages
Download PDF

The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype

  • Jacqueline Nathansen,
  • Vasyl Lukiyanchuk,
  • Linda Hein,
  • Maya-Isabel Stolte,
  • Kerstin Borgmann,
  • Steffen Löck,
  • Ina Kurth,
  • Mechthild Krause,
  • Annett Linge and
  • Anna Dubrovska
Med. Sci. Forum2021, 3(1), 5;https://doi.org/10.3390/IECC2021-09224

31 January 2021

Despite being the sixth most common cancer type worldwide, head and neck squamous cell carcinoma (HNSCC) exhibits low five-year survival rates for advanced-stage patients. The local control probability after radiotherapy crucially depends on efficien...

Full Article
  • Abstract
  • Open Access
1,006 Views
1 Page
Download PDF

Does the Modification of Serine 477 of DNA Mismatch Repair Protein MLH1 Play a Role in Cell Proliferation?

  • May-Britt Firnau and
  • Angela Brieger
Med. Sci. Forum2021, 3(1), 8;https://doi.org/10.3390/IECC2021-09228

31 January 2021

MutLα, a heterodimer consisting of MLH1 and PMS2, is a key player in the DNA mismatch repair (MMR) system and of great importance to correct incorporation errors that occur during DNA replication. Previously, we identified that posttranslational phos...

Full Article
  • Abstract
  • Open Access
1,127 Views
1 Page
Download PDF

Evidence of the Nerve–Cancer Connection in Female Reproductive Cancers

  • Sonia M. Rodrigues Oliveira,
  • Hubert Hondermarck and
  • Phillip Jobling
Med. Sci. Forum2021, 3(1), 9;https://doi.org/10.3390/IECC2021-09199

31 January 2021

In recent years, the infiltration of tumors by axons or nerves has been increasingly reported and has been linked to poor prognosis. This includes, among others, publications by Magnon et al. (Science 341, 2013); and our own work (Faulkner et al., FA...

Full Article
  • Proceeding Paper
  • Open Access
4 Citations
2,230 Views
6 Pages
Download PDF

The Electrochemical Behavior of Methotrexate upon Binding to the DNA of Different Cell Lines

  • Douglas Vieira Thomaz and
  • Pierre Alexandre dos Santos
Med. Sci. Forum2021, 3(1), 16;https://doi.org/10.3390/IECC2021-09215

29 January 2021

Methotrexate (MTX) is a widely used anticancer agent whose DNA binding properties are well known. Despite its consolidated usage in the therapeutics of cancer, the physicochemical features of MTX binding to healthy and neoplastic DNA are still not fu...

Full Article
  • Abstract
  • Open Access
1,172 Views
1 Page
Download PDF

Exploiting DNA Repair Defect in Triple Negative Breast Cancer Using CDK Inhibition Strategy

  • Carolina Velázquez,
  • Esin Orhan,
  • Imene Tabet,
  • Lise Fenou,
  • Laura Boudarel,
  • William Jacot,
  • Claude Sardet and
  • Charles Theillet
Med. Sci. Forum2021, 3(1), 13;https://doi.org/10.3390/IECC2021-09212

29 January 2021

Triple-negative breast cancer (TNBC), representing 15% of breast carcinomas, is an aggressive breast cancer subtype with a high probability of metastasis and limited treatment options. Noticeably, BRCA-deficiency occurs in 25% of the TNBCs and result...

Full Article
  • Abstract
  • Open Access
1,417 Views
2 Pages
Download PDF

Differences in Durability of PARP Inhibition by PARP Inhibitors in Ovarian Cancer Cells

  • Hannah Louise Smith,
  • Asima Mukhopadhyay,
  • Yvette Drew,
  • Elaine Willmore and
  • Nicola Curtin
Med. Sci. Forum2021, 3(1), 11;https://doi.org/10.3390/IECC2021-09194

29 January 2021

Background: PARP inhibitors (PARPi) exploit defects in homologous recombination repair (HRR) to selectively kill tumour cells. Continuous PARP inhibition is required for cytotoxicity. PARPis rucaparib, olaparib, and niraparib have been approved for u...

Full Article

of 2

Go to next page

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Med. Sci. Forum - ISSN 2673-9992
Imprint
Download Flyer